Patents Assigned to AstraZeneca AB
  • Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors
    Patent number: 10183947
    Abstract: The present application relates to novel compounds of formula (I) to their utility in treating and/or preventing clinical conditions including cardiovascular diseases (CVD), to methods for their therapeutic use, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Grant
    Filed: May 3, 2016
    Date of Patent: January 22, 2019
    Assignee: ASTRAZENECA AB
    Inventors: Johan Olof Broddefalk, Hans Fredrik Emtenäs, Kenneth Lars Granberg, Malin Anita Lemurell, Daniel Tor Pettersen, Alleyn Thomas Plowright, Lars Johan Andreas Ulander
  • Pharmaceutical compositions comprising AZD9291
    Patent number: 10183020
    Abstract: The present invention relates to pharmaceutical compositions suitable for oral administration, and more particularly to pharmaceutical compositions, including pharmaceutical tablet compositions, containing N-(2-{2-dimethylaminoethyl-methyl-amino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide (“AZD9291”) or a pharmaceutically acceptable salt thereof, wherein such compositions comprise a certain amount of microcrystalline cellulose and at least one other pharmaceutical diluent.
    Type: Grant
    Filed: January 2, 2015
    Date of Patent: January 22, 2019
    Assignee: AstraZeneca AB
    Inventors: Cindy Finnie, Steven Anthony Raw, David Wilson
  • Composition for inhalation
    Patent number: 10166247
    Abstract: The invention relates to a formulation comprising formoterol and budesonide for use in the treatment of respiratory diseases. The composition further contains HFA 227, PVP and PEG, preferably PVP K25 and PEG 1000.
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: January 1, 2019
    Assignee: AstraZeneca AB
    Inventors: Nayna Govind, Maria Marlow
  • PHARMACEUTICAL COMPOSITION COMPRISING A POTENT INHIBITOR OF URAT1
    Publication number: 20180360761
    Abstract: The present invention relates to pharmaceutical compositions containing 2-((3-(4-cyanonaphthalen-1-yl)pyridine-4-yl)thio)-2-methylpropanoic acid or a pharmaceutically acceptable salt (hereinafter referred to as the “Agent”), more particularly to orally deliverable compositions containing the Agent; to the use of said compositions as a medicament; and to processes for the preparation of said compositions.
    Type: Application
    Filed: December 7, 2016
    Publication date: December 20, 2018
    Applicants: Ardea Biosciences, Inc., AstraZeneca AB
    Inventors: Joanne REILAND WAKEMAN, Colin ROWLINGS, Sha LIU, Gerry BURKE, Christian VON CORSWANT, Christer TANNERGREN, Johan HJÄRTSTAM
  • Chemical compounds
    Patent number: 10149839
    Abstract: The specification relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: December 11, 2018
    Assignee: AstraZeneca AB
    Inventors: James Stewart Scott, Thomas Andrew Moss, Daniel Hillebrand O'Donovan, Johannes Wilhelmus Maria Nissink, Samantha Jayne Hughes, Bernard Christophe Barlaam, Dan Anders Broo, Bin Yang, Jeffrey Gilbert Varnes, Dedong Wu
  • Chemical compounds
    Patent number: 10130617
    Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1 to R5 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: November 20, 2018
    Assignee: AstraZeneca AB
    Inventors: Robert Hugh Bradbury, David Buttar, Christopher De Savi, Craig Samuel Donald, Richard Albert Norman, Alfred Arthur Rabow, Gordon Stuart Currie, Heather Redfearn, Nadim Akhtar, Helen Elizabeth Williams, Matthew Osborne, Neda Yavari
  • Chemical compounds
    Patent number: 10131663
    Abstract: The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: November 20, 2018
    Assignee: AstraZeneca AB
    Inventors: Bernard Christophe Barlaam, Daniel Hillebrand O'Donovan, Samantha Jayne Hughes, Thomas Andrew Moss, Johannes Wilhelmus Maria Nissink, James Stewart Scott, Bin Yang
  • Chemical compounds
    Patent number: 10125135
    Abstract: The specification relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: November 13, 2018
    Assignee: AstraZeneca AB
    Inventors: Bin Yang, Jeffrey Gilbert Varnes, James Stewart Scott, Thomas Andrew Moss, Daniel Hillebrand O'Donovan, Johannes Wilhelmus Maria Nissink, Samantha Jayne Hughes, Bernard Christophe Barlaam
  • Stable anti-IFNAR1 formulation
    Patent number: 10125195
    Abstract: The present invention relates to a stable, low viscosity antibody formulation, wherein the formulation comprises a high concentration of anti-INFAR1 antibody. In some embodiments, the invention relates in general to a stable antibody formulation comprising about 100 mg/mL to about 200 mg/mL of an antibody or fragment thereof that specifically binds human interferon alpha 1 (INFAR1); about 20 mM to about 80 mM of a lysine or a salt thereof; about 0.02% to about 0.06% of a surfactant; an uncharged excipient; and a formulation buffer. In some embodiments, the invention is directed to a container, dosage form and/or kit. In some embodiments, the invention is directed to a method of making and using the stable antibody formulation.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: November 13, 2018
    Assignee: AstraZeneca AB
    Inventors: Roberto Depaz, Natalie DeJesus, Jared Bee
  • Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer
    Publication number: 20180318287
    Abstract: The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where x, R1, R2, R3, R4 and R5 have any of the meanings defined herein. The specification also relates to the use of compounds of Formula (I) and salts thereof to treat or prevent ATM mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising substituted imidazo[4,5-c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; and intermediates useful in such manufacture.
    Type: Application
    Filed: November 2, 2016
    Publication date: November 8, 2018
    Applicant: ASTRAZENECA AB
    Inventors: Kurt Gordon PIKE, Bernard Christophe BARLAAM, Thomas Anthony HUNT, Andrew John EATHERTON
  • Arginase inhibitors and methods of use
    Patent number: 10118936
    Abstract: The present invention is directed to arginase inhibitor compounds of formula IA or formula IB: or a pharmaceutically acceptable salt thereof, compositions containing these compounds, and methods of their use for the treatment and diagnosis of conditions characterized by upregulation of arginase, abnormally high arginase activity, or by abnormally low nitric oxide synthase activity.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: November 6, 2018
    Assignees: The Trustees of the University of Pennsylvania, AstraZeneca AB
    Inventors: David W. Christianson, Bruce Edward Tomczuk, Richard Scott Pottorf, Andrew Vargha Colasanti, Gary Lee Olson
  • Protein kinase B inhibitors
    Patent number: 10059714
    Abstract: The invention relates to a novel group of compounds of Formula (I) or salts thereof: wherein Y, Z1, Z2, R1, R4, R5 and n are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through protein kinase B (PKB) such as cancer. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by PKB using said compounds and methods for preparing compounds of Formula (I).
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: August 28, 2018
    Assignee: AstraZeneca AB
    Inventors: Paul David Johnson, Andrew Leach, Richard William Arthur Luke, Zbigniew Stanley Matusiak, Jeffrey James Morris
  • Chemical Compounds
    Publication number: 20180237443
    Abstract: The present disclosure concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1, R2 and R3 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cancer.
    Type: Application
    Filed: January 18, 2018
    Publication date: August 23, 2018
    Applicant: AstraZeneca AB
    Inventors: Clifford David Jones, Richard Andrew Ward, Mark Andrew Graham, Steven Swallow, Andrew Hornby Dobson, James Francis McCabe
  • PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS
    Publication number: 20180237439
    Abstract: The present application relates to novel compounds of formula (I) to their utility in treating and/or preventing clinical conditions including cardiovascular diseases (CVD), to methods for their therapeutic use, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Application
    Filed: May 3, 2016
    Publication date: August 23, 2018
    Applicant: ASTRAZENECA AB
    Inventors: Johan Olof BRODDEFALK, Hans Fredrik EMTENÄS, Kenneth Lars GRANBERG, Malin Anita LEMURELL, Daniel Tor PETTERSEN, Alleyn Thomas PLOWRIGHT, Lars Johan Andreas ULANDER
  • Compounds and their use as BACE inhibitors
    Patent number: 10053453
    Abstract: The present application relates to compounds of formula (I), (Ia), or (Ib) and their pharmaceutical compositions/preparations. This application further relates to methods of treating or preventing A?-related pathologies such as Down's syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia, including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: August 21, 2018
    Assignee: AstraZeneca AB
    Inventors: Roland Bürli, Mark E. Duggan, Jörg Holenz, Patrik Johansson, Karin Kolmodin, Philip Vellacott Thorne, Michael John McKenzie
  • [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES
    Publication number: 20180230158
    Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1, R2 and n have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use as anti-proliferative and/or cell-killing agents.
    Type: Application
    Filed: April 11, 2018
    Publication date: August 16, 2018
    Applicant: AstraZeneca AB
    Inventors: Robert Hugh BRADBURY, Alfred Arthur Rabow, Michael James Waring, James Francis McCabe, Steven Christopher Glossop, Arshed Mahmood, Zoe Ann Cotter
  • Therapeutic polymeric nanoparticles and methods of making and using same
    Patent number: 10047072
    Abstract: Described herein are polymeric nanoparticles that include a therapeutic agent which is 2-(3-((7-(3-(ethyl(2-hydroxyethyl)amino)propoxy)quinazolin-4-yl)amino)-1H-pyrazol-5-yl)-N-(3-fluorophenyl)acetamide (also known as AZD1152 hqpa) or a pharmaceutically acceptable salt thereof, and methods of making and using such therapeutic nanoparticles.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: August 14, 2018
    Assignee: ASTRAZENECA AB
    Inventors: Marianne Bernice Ashford, James Martin Nolan, III, Eyoung Shin, Young-Ho Song, Greg Troiano, Hong Wang
  • 1,3,4-thiadiazole compounds and their use in treating cancer
    Patent number: 10040788
    Abstract: The specification relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where Q, R, R1 and R2 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent GLS1 mediated disease, including cancer. The specification further relates to crystalline forms of compounds of Formula (I) and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating GLS1 kinase mediated disease, including cancer, using such compounds and salts.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: August 7, 2018
    Assignees: AstraZeneca AB, Cancer Research Technology Limited
    Inventors: Maurice Raymond Verschoyle Finlay, Chukuemeka Tennyson Ekwuru, Mark David Charles, Piotr Antoni Raubo, Jonathan James Gordon Winter, Johannes Wilhelmus Maria Nissink
  • 1,3,4-thiadiazole compounds and their use in treating cancer
    Patent number: 10040789
    Abstract: A compound of Formula (I): or a pharmaceutically acceptable salt thereof, is described. Q can be pyridazin-3-yl, 6-fluoropyridazin-3-yl; R1 can be H; R2 and R3 can each independently be C1-C6 alkyl, or R2 and R3 taken together are —(CH2)3—; or R1 and R2 taken together can be —(CH2)2— and R3 can be —CH3; R4 halo, —CH3, —OCH3, —OCHF2, —OCF3, or —CN; and n can be 0, 1, or 2. The compound of formula (I) can inhibit glutaminase, e.g., GLS1.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: August 7, 2018
    Assignees: AstraZeneca AB, Cancer Research Technology Limited
    Inventors: David Robert Perkins, Maurice Raymond Verschoyle Finlay, Johannes Wilhelmus Maria Nissink, Piotr Antoni Raubo, Peter Duncan Smith, Andrew Bailey
  • 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents
    Patent number: RE47047
    Abstract: The present invention relates to compounds of formula I, processes for their production and their use as anti-inflammatory agents.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: September 18, 2018
    Assignees: ASTRAZENECA AB, BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Markus Berger, Hartmut Rehwinkel, Thomas Zollner, Ekkehard May, Jorma Hassfeld, Heike Schaecke